

6. Literaturverzeichnis

1. Agha A, Schlüter H, König S, Biel K, Tepel M, Zidek W: A novel platelet derived renal vasoconstrictor agent in normotensives and essential hypertensives. *J Vase Res.* 1992 ; 29: 281-289.
2. Appel LJ : Lifestyle modification as a means to prevent and treat high blood pressure. *J Am Soc Nephrol.* 2003; 14: 99-102.
3. Bianchi G, Fox U, Di Francesco GF, Giovanetti AM, Pagetti D: Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. *Clin Sci Mol Med.*1974; 47: 435-448.
4. Brown TA: *Moderne Genetik: Eine Einführung.* Spektrum Akademischer Verlag, Heidelberg, 1993.
5. Bühling KJ, Lepenies J, Witt K: *Intensivkurs: Allgemeine und spezielle Pathologie.* Urban & Fischer, München, 2000.
6. Busse R, Ogilvie A, Pohl U: Vasomotor activity of diadenosine triphosphate and diadenosine tetraphosphate in isolated arteries. *Am J Physiol.* 1988; 254: 828-832.
7. Chen K, Wie Y, Sharp GC, Braley-Mullen H: Inhibition of TGFbeta 1 by anti-TGFbeta 1 antibody or lisinopril reduces thyroid fibrosis in granulomatous experimental autoimmune thyroiditis. *J Immunol.* 2002; 169: 6530-6538.
8. Classen M, Diehl V, Kochsiek K, Schmiegel W: *Innere Medizin.* Urban & Fischer Verlag, München, 2003.

9. Constantinescu CS, Goodman DB, Ventura ES: Captopril and Isinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. *Immunol Lett.* 1998; 62: 25-31.
10. Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P, Diethelm AG: Remission of essential hypertension after renal transplantation. *N Engl J Med.* 1983; 309: 1009-1014.
11. Dahl LK, Knudsen KD, Iwai J: Humoral transmission of hypertension: evidence from parabiosis. *Circ Res.* 1969; 24: 21-33.
12. Dinh DT, Frauman AG, Johnston CI, Fabiani ME: Angiotensin receptors: distribution, signalling and function. *Clin Sci.* 2001; 100: 481-492.
13. Dezso B, Jacobsen J, Poulsen K: Evidence for the presence of angiotensins in normal, unstimulated alveolar macrophages and monocytes. *J Hypertens.* 1989; 7: 5-11.
14. Dorer FE, Kahn JR, Lentz KE, Levine M, Skeggs LT: Purification and properties of angiotensin-converting-enzyme from hog lung. *Circ Res.* 1972; 31: 356-366.
15. Dzau VJ: Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. *J Hypertens.* 1989; 7: 933-936.
16. Fierens FL, Vanderheyden PM, Roggeman C, Vande Gucht P, De Bocher JP, Vauquelin G: Distinct binding properties of the AT(1) receptor antagonist [(3)] candesartan to intact cells and membrane preparations. *Biochem Pharmacol.* 2002; 63: 1273-1279.

17. Girndt J: Praxis der Hochdruckkrankheiten. Schattauer Verlag, Stuttgart, 1990.
18. Gobom J, Schuerenberg M, Mueller M, Theiss D, Lehrach H, Nordhoff H: Alpha-cyano-4-hydroxycinnamic acid affinity sample preparation. A protocol for MALDI-MS peptide analysis in proteomics. *Anal Chem.* 2001; 73: 434-438.
19. Gomez RA, Norling LL, Wilfong N, Isakson P, Lynch KR, Hock R, Quesenberry P: Leukocytes synthesize angiotensinogen. *Hypertension.* 1993; 21: 470-475.
20. Goosens GH, Blaak EE, van Baak MA: Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. *Obes Rev.* 2003;4: 43-55.
21. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM: Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. *J Hypertens.* 2002; 20: 965-973.
22. Greminger P: Renovaskuläre Hypertonie. *Schweiz Med Wochenschr.* 1996; 126: 1314-1320.
23. Greminger P, Vetter W, Groth H, Lüscher T, Tenschert W, Siegenthaler W, Vetter H: Captopril in Cushing's syndrome. *Klein Wschr.* 1984; 62: 855-858.
24. Hahn JM: Checkliste Innere Medizin. Georg Thieme Verlag, Stuttgart, 1997.
25. Herold G: Innere Medizin. Gerd Herold Verlag, Köln, 2001.
26. Inagami T: A memorial to Robert Tiegerstedt: the centennial of renin discovery. *Hypertension.* 1998; 32: 953-57.

27. Jankowski J, Tepel M, van der Giet M, Tente IM, Henning L, Junker R, Zidek W, Schlüter H: Identification and characterization of P(1), P(7)-Di(adenosine-5')-hepatophosphate from human platelets. *J Biol Chem.* 1999; 274: 23926-23931.
28. Juhasz P, Roskey MT, Smirnov IP, Haff LA, Vestal ML, Martin SA: Applications of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass-spectrometry to oligonucleotide analysis. *Anal Chem.* 1996 68: 941-946.
29. Langenfeld H, Burrows G: Kochbuch der Internistischen Intensivmedizin. FrankoMed Fachverlag, 2001.
30. Le MT, Vanderheyden PM, Szaszak M, Hunyady L, Vauquelin G: Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N- and C-terminal residues of angiotensin II during AT1 receptor activation. *J Biol Chem.* 2002; 277: 23107-23110.
31. Leung PS, Chan HC, Wong PY: Immunohistochemical localization of angiotensin II in the mouse pancreas. *Histochem J.* 1998; 30: 121-125.
32. Lottspeich F, Zorbach H: Bioanalytik. Spektrum Akademischer Verlag, Heidelberg, 1998.
33. Lüscher TF, Boulanger CM, Dohi Y, Yang ZH: Endothelium-derived contracting factors. *Hypertension* 1992; 19: 117-30.
34. Machleidt C: Nephrologie; Pathophysiologie, Klinik und Praxis. Georg Thieme Verlag, Stuttgart, 1998.
35. McCumbee WD, Wright GL: Partial purification of a hypertensive substance from rat erythrocytes. *Can J Physiol Pharmacol.* 1985; 63: 1321-1326.

36. Medzihradzky K, Campbell J, Baldwin M, Falick A, Juhasz P, Vestal M, Burlingame A: The characteristics of peptide collision-induced dissociation using high-performance MALDI-TOF/TOF Tandem mass spectrometer. *Anal Chem.* 2000; 72: 552-558.
37. Morgan L, Pipkin FB, Kalsheker N: Angiotensinogen: molecular biology, biochemistry and physiology. *Int J Biochem Cell Biol.* 1996; 28: 1211-1222.
38. Naftilan AJ: Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. *Curr Opin Nephrol Hypertens.* 1994; 3: 218-227.
39. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM: Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. *J Clin Invest.* 1999; 104: 1693-1701.
40. Pfreundschuh M, Schölmerich J: *Pathophysiologie, Pathobiochemie.* Urban & Fischer Verlag. München. 2000.
41. Phillips MI, Speakman EA, Kimura B: Levels of angiotensin and molecular biology of the tissue renin angiotensin system. *Regul Pept.* 1993; 43: 1-20.
42. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD: Evidence that macrophages in atherosclerotic lesions contain angiotensin II. *Circulation.* 1998; 98: 800-807.
43. Potts JT: Erkrankungen der Nebenschilddrüse sowie andere hyper- und hypokalzämische Störungen. In: *Harrisons TR: Innere Medizin.* McGraw-Hill Verlag, New York, 1999.

44. Raff T, van der Giet M, Endemann D, Wiederholt T, Paul M: Design and testing of beta-actin primers for RT-PCR that do not co-amplify processed pseudogenes. *Biotechniques*. 1997; 23: 456-460.
45. Ralevic V, Hoyle CH, Burnstock G: Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries. *J Physiol*. 1995; 483: 703-713.
46. Reinwein D, Benker G: *Klinische Endokrinologie und Diabetologie*. Schattauer Verlag, Stuttgart, 1992.
47. Rodgers KE, Xiong S, DiZerega GS: Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. *Cancer Chemother Pharmacol*. 2003; 51: 97-106.
48. Rodgers KE, Xiong S, Steer R, DiZerega GS: Effect of angiotensin II on hematopoietic progenitor cell proliferation. *Stem Cells*. 2000; 18: 287-294.
49. Rupp H, *Hypertonie und Alkohol: zentrale und periphere Mechanismen*: *Archiv-Herz*. 1996; 04: 258-264.
50. Saris JJ, van Dijk MA, Kroon I, Schalekamp MA, Danser AH: Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. *Hypertension*. 2000; 32: 764-768.
51. Schlüter H, Grobeta I, Bachmann J, Kaufmann R, van der Giet M, Tepel M, Nofer JR, Assman G, Karas M, Jankowski J, Zidek W: Diadenosine phosphates and the physiological control of blood pressure. *Nature*. 1994; 367: 186-188.
52. Schmalz AA: *Herz-Kreislauf-Erkrankungen*, in: Niessen KH (Hrsg): *Pädiatrie*. 337, 1993.

53. Schölmerich J, Straub RH, Elsner D, Krämer BK: Hexal Memomed Innere Medizin. Urban & Schwarzenberg Verlag, München, 1999.
54. Siegenthaler W, Kuhlmann U: Hypertonie. In: Siegenthaler W: Differentialdiagnose innerer Krankheiten. Georg Thieme Verlag, Stuttgart, 2000.
55. Silbernagl S, Lang F: Taschenatlas der Pathophysiologie. Georg Thieme Verlag, Stuttgart, 1998.
56. Sinclair AM, Isles CG, Brown J, Cameron H, Murray GD, Robertson JWK: Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987; 147: 1289-1293.
57. Stengel B, Tarver-Carr ME, Powe NR, Ebhardt MS, Brancati FL: Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003; 14(4): 479-487.
58. Stryer L: Biochemie. Spektrum Akademischer Verlag, Heidelberg, 1996.
59. Suzuki Y, Shirato I, Okumara K, Ravetch JV, Takai T, Tomino Y, Ra C: Distinct contribution of Fc receptors and angiotensin II-dependent pathway in anti-GBM glomerulonephritis. Kidney Int. 1998; 54: 1166-1174.
60. Suzuki Y, Gomez-Guerrero C, Shirato I, Lopez-Franco O, Hernandez-Vargas P, Sanjuan G, Ruiz-Ortega M, Sugaya T, Okumura K, Tomino Y, Ra C, Egido J: Susceptibility to T cell-mediated injury in immune complex disease is linked to activation of renin-angiotensin system: the role of NF-AT pathway. J Immunol. 2002; 169: 4136-4146.

61. Tepel M, Schlotmann R, Barenbrock M, Kisters K, Klaus T, Spieker C, Walter M, Meyer C, Bretzel RG, Zidek W: Lymphocytic Na(+)-H+ exchange increases after an oral glucose challenge. *Circ Res.* 1995; 77: 1024-1029.
62. Van der Giet M, Khattab M, Borgel J, Schlüter H, Zidek W: Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. *Br J Pharmacol.* 1997; 120: 1453-1460.
63. Wagner J: *Praktische Kardiologie für Studium, Klinik und Praxis.* Walter de Gruyter Verlag, 1985.
64. Weinstock JV, Blum AM: Granuloma macrophages in murine schistosomiasis mansonii generate components of the angiotensin system. *Cell Immunol.* 1984; 39-45.
65. Williams GH: Hypertoniebedingte Gefäßerkrankungen. In: *Harrisons TR (Hrsg): Innere Medizin.* 1628-1643, McGraw-Hill Verlag, Frankfurt a. M., 1999.
66. Williams GH: Erkrankungen der Nebennierenrinde. In: *Harrisons TR (Hrsg): Innere Medizin.* 2392-2417, McGraw-Hill Verlag, Frankfurt a. M., 1999.
67. Witzleb E: Funktionen des Gefäßsystems. In: *Schmidt RF, Thews G: Physiologie des Menschen.* Springer Verlag, Berlin Heidelberg, 1995.
68. Wolff HP, Weihrauch TR: *Internistische Therapie.* Urban & Schwarzenberg Verlag, 2000.
69. 1999 World Health Organization-International Society of Hypertension (WHO): Guidelines for the Management of Hypertension. Guideline Subcommittee. *J. Hypertens.* 1999; 17: 151-183.

-
70. Zidek W, Sachinidis A, Heckmann U, Storkebaum W, Schmidt W, Vetter H: Humoral factors in primary hypertension. *J Clin Hypertens*. 1985; 1: 257-264.
 71. Zidek W, Heckmann U, Losse H, Vetter H: Effects on blood pressure of cross circulation between spontaneously hypertensive and normotensive rats. *Clin Expert Hypertens Art*. 1986; 8: 347-354.